Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00330655 · ClinicalTrials.gov registry record · Phase 4

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

A Phase 4 study, sponsored by Mclean Hospital.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target

NCT00330655: Completed Phase 4 study, sponsored by Mclean Hospital.

NCT00330655 is a Phase 4 study that has completed, run by Mclean Hospital. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00330655, a Phase 4 study, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target

Study Summary

We hypothesize that memantine may be a safe and effective treatment for moderate to severe binge eating disorder associated with obesity. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have moderate to severe binge eating disorder and are obese will be treated with open-label memantine. Following this 12-week treatment phase, subjects may be eligible to continue into an extension phase which will last an additional 12 weeks. During the extension phase subjects will continue open-label memantine treatment.

Interventions

  • DRUG memantine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-05
Est. Completion 2007-07
Phase Phase 4
Mclean Hospital

140 total trials

What the finished NCT00330655 record still lists

NCT00330655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which memantine is the first listed.

NCT00330655 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00330655 about?

NCT00330655 is a clinical study titled "An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder". We hypothesize that memantine may be a safe and effective treatment for moderate to severe binge eating disorder associated with obesity. During this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have moderate to severe binge eating disorder...

What is the current status of trial NCT00330655?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2006-05. Estimated completion is 2007-07.

What interventions are being tested in trial NCT00330655?

The interventions under investigation include: memantine (DRUG).

Who is sponsoring clinical trial NCT00330655?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00330655's enrollment target sits among peer trials

15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00330655, the US trial registry maintained by the National Library of Medicine. NCT00330655 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.